Sign In
Buy MLYS
$25.61
+0.240 (+0.95%)
At Close: Jun 23, 2026
– Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impa
Wall Street Analysts Think Mineralys Therapeutics, Inc. (MLYS) Could Surge 27.55%: Read This Before Placing a Bet
10:55am, Friday, 05'th Dec 2025
The mean of analysts' price targets for Mineralys Therapeutics, Inc. (MLYS) points to a 27.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agr
This Fund Leaned Into 2025's Big Biotech Rally with a $9.5 Million Bet on Mineralys
11:34am, Thursday, 27'th Nov 2025
New York City-based Findell Capital Management added 250,000 shares of MLYS, valued at $9.5 million, in the third quarter. The purchase marked a new position for Findell, which reported holding no sha
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 26'th Nov 2025
RADNOR, Pa., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and relate
Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) CFO Sells $5,364,237.12 in Stock
05:12am, Sunday, 16'th Nov 2025
Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) CFO Adam Scott Levy sold 119,524 shares of the company's stock in a transaction dated Tuesday, November 11th. The stock was sold at an ave
Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) CEO Sells $9,088,000.00 in Stock
04:38am, Sunday, 16'th Nov 2025
Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) CEO Jon Congleton sold 200,000 shares of the firm's stock in a transaction dated Tuesday, November 11th. The stock was sold at an average
Mineralys Therapeutics, Inc. (MLYS) Q3 2025 Earnings Call Transcript
07:11pm, Monday, 10'th Nov 2025
Mineralys Therapeutics, Inc. ( MLYS ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Jon Congleton - President, CEO & Director Adam Levy - CFO & Secretary David Rodman - Chie
Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
04:05pm, Monday, 10'th Nov 2025
– Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 – – Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 – – Conference
– Late-breaking presentation of Explore-CKD trial at ASN Kidney Week – – Pivotal Phase 3 Launch-HTN trial featured in the “Best of JAMA and NEJM” session - RADNOR, Pa., Nov. 07, 2025 (GLOBE
KLP Kapitalforvaltning AS Makes New $91,000 Investment in Mineralys Therapeutics, Inc. $MLYS
03:08am, Wednesday, 22'nd Oct 2025
KLP Kapitalforvaltning AS acquired a new position in shares of Mineralys Therapeutics, Inc. (NASDAQ: MLYS) during the undefined quarter, according to the company in its most recent 13F filing with the
~ Late-breaking Phase 2 trial data evaluating the safety and efficacy of 25 mg of lorundrostat in participants with hypertension and comorbid CKD to be presented~ ~ Phase 3 data of the Launch-HTN Tria
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Receives $43.50 Average Price Target from Brokerages
01:14am, Monday, 20'th Oct 2025
Shares of Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) have been given an average recommendation of "Moderate Buy" by the seven research firms that are covering the stock, Marketbeat
Mineralys: Lorundrostat Continues To Deliver Hypertension Market Expansions
03:17pm, Wednesday, 01'st Oct 2025
Mineralys Therapeutics, Inc. advances lorundrostat, its lead aldosterone inhibitor, for uncontrolled and resistant hypertension with pivotal Phase 3 successes. Mineralys achieved positive Phase 2 resu
Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension
08:00am, Tuesday, 30'th Sep 2025
~ Topline results from the EXPLORE-OSA trial are anticipated in 1Q 2026 ~ RADNOR, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutica
Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock: Should You Buy?
01:01pm, Monday, 29'th Sep 2025
Does Mineralys Therapeutics, Inc. (MLYS) have what it takes to be a top stock pick for momentum investors? Let's find out.
